丹申苏和伊尔贝沙坦之间的药物相互作用及其潜在的机制
1Department of the Pharmacy, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
概括
丹申苏通过抑制CYP2C9.9的作用显著增加了老鼠对伊尔贝沙坦的暴露. 这种相互作用强调了需要对danshensu和irbesartan同时使用进行临床考虑的需要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物代谢和药理动力学
- 自然产品化学 自然产品化学
背景情况:
- 伊尔贝沙坦是一种广泛使用的血管激素II受体阻塞剂,用于高血压.
- 丹申苏,Salvia miltiorrhiza的主要活性成分,以其心血管益处而闻名.
- 草药和常规药物之间的潜在药物相互作用需要进行彻底的调查.
研究的目的:
- 为了阐明danshensu对老鼠irbesartan的药理动力学影响.
- 研究这种潜在药物相互作用的潜在机制,重点关注代谢途径.
- 评估danshensu对细胞染色体P450 2C9 (CYP2C9) 的活性的影响.
主要方法:
- 斯普拉格-道利大鼠被单独或与danshensu. irbesartan一起使用.
- 液体染色学-并联质谱学 (LC-MS/MS) 用于量化伊尔贝萨坦的度.
- 实验室研究评估了danshensu在老鼠肝显微体 (RLMs) 和CYP2C9活性中对irbesartan代谢稳定性的影响.
主要成果:
- 丹申苏显著增加了伊尔贝萨坦在曲线下的面积 (AUC) 和最大度 (Cmax).
- 丹申苏延长了伊尔贝沙坦的半衰期 (t1/2) 并降低了其清除率.
- 在体外,danshensu增强了伊尔贝沙坦的代谢稳定性,并抑制了CYP2C9活性,IC50为35.74μM.
结论:
- 丹申苏增强了老鼠对伊尔贝沙坦的全身暴露,主要是通过抑制由CYP2C9介导的新陈代谢.
- 这些发现表明danshensu和irbesartan之间存在显著的药理动力学相互作用.
- 需要进一步的临床研究来证实这种相互作用,并指导患者安全同时服用.
更多相关视频
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
261
08:35Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.2K
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
613
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
01:22Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370